Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 30, 2026Journal of Clinical Oncology

Efficacy and safety of CAR T-cell therapy in hematologic malignancies: A systematic review and meta-analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

HPHem PrajapatiMMMansi ModyJKJay Kakadiya

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis evaluates CAR T-cell therapy efficacy in hematologic malignancies, indicating significant therapeutic potential but notable risks.

Key Points

  • To evaluate the efficacy and safety of CAR T-cell therapy in patients with hematologic malignancies through a systematic review and meta-analysis.
  • Conducted a literature search to identify 47 studies (31 trials, 10 observational, 6 case series)
  • Estimated pooled overall response rate (ORR), complete response (CR), progression-free survival (PFS), and overall survival (OS) along with evaluating toxicities
  • Assessed between-study heterogeneity and publication bias.
  • Pooled ORR was 75% (95% CI 70-80%) and CR was 45% (95% CI 40-50%)
  • At 12 months, PFS was 60% (95% CI 55-65%) and OS was 72% (95% CI 67-77%)
  • Common toxicities included CRS in 85% of patients (grade ≥3: 20%), neurotoxicity in 40% (grade ≥3: 15%), and treatment-related mortality at 5%.

Cite This Study

Prajapati et al. (2026) studied this question.

synapsesocial.com/papers/6a1a7f760307b78509431aa7https://doi.org/10.1200/jco.2026.44.16_suppl.e18575
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis2025
  2. 2Efficacy and Safety of CAR T-cell Therapy in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis2025
  3. 3Efficacy of CAR-T cell therapy in chronic lymphocytic leukemia: A meta-analysis2025
  4. 4CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.2026
  5. 5Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis2025